Literature DB >> 26278692

Comparison of clinical characteristics and outcomes between combined pulmonary fibrosis and emphysema associated with usual interstitial pneumonia pattern and non-usual interstitial pneumonia.

Keishi Sugino1, Yasuhiko Nakamura, Takafumi Ito, Takuma Isshiki, Susumu Sakamoto, Sakae Homma.   

Abstract

BACKGROUND: Recently, combined pulmonary fibrosis and emphysema (CPFE) has been recognized worldwide. However, actually CPFE had a variety of extent of emphysema or pulmonary fibrosis.
OBJECTIVES: The objectives of this study were to compare the clinical characteristics and outcomes between CPFE associated with usual interstitial pneumonia pattern (UIP) and CPFE with non-UIP divided based on chest high resolution computed tomography (HRCT) images, as well as to elucidate prognostic factors.
METHODS: A cohort of 57 CPFE and 64 IPF patients at a single institution was analyzed retrospectively. The HRCT imaging patterns of definite UIP pattern and possible UIP pattern were defined as UIP, and inconsistent with UIP pattern as non-UIP. Clinical characteristics and outcomes were compared in 3 subgroups with CPFE/UIP, CPFE/non-UIP, and IPF alone, respectively. The prognostic factors were performed using Cox proportional hazards.
RESULTS: The incidences of primary lung cancer and acute exacerbation (AE) were 10.4%/10.9% in CPFE/UIP, 0%/27.3% in CPFE/non-UIP, and 6.3%/35.9% in IPF, respectively. The survival in CPFE/UIP had significantly worse than that in other 2 subgroups (CPFE/non-UIP, IPF) (P = 0.011, P = 0.043). The multivariate Cox regression model showed that the prognostic factors of CPFE were UIP pattern and high-composite physiologic index (CPI). CPI thresholds of 45 provided the greatest prognostic separation in patients with CPFE. CPFE/UIP with high-CPI (CPI ≥ 45) had a worst prognosis compared with the other groups.
CONCLUSIONS: This study demonstrated that the presence of UIP pattern and high-CPI in CPFE patients were associated with poorer mortality.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26278692

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  6 in total

1.  An increased risk of lung cancer in combined pulmonary fibrosis and emphysema patients with usual interstitial pneumonia compared with patients with idiopathic pulmonary fibrosis alone: a systematic review and meta-analysis.

Authors:  Qianqian Chen; Ping Liu; Hong Zhou; Hui Kong; Weiping Xie
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

2.  Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation.

Authors:  Sung Woo Moon; Moo Suk Park; Young Sam Kim; Joon Jang; Jae Ho Lee; Choon-Taek Lee; Jin-Haeng Chung; Hyo Sup Shim; Kyung Won Lee; Seung-Seob Kim; Sang Hoon Lee; Ho Il Yoon
Journal:  BMC Pulm Med       Date:  2019-10-15       Impact factor: 3.317

3.  Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study.

Authors:  Chihiro Hirano; Shinichiro Ohshimo; Yasushi Horimasu; Hiroshi Iwamoto; Kazunori Fujitaka; Hironobu Hamada; Nobuoki Kohno; Daisuke Komoto; Kazuo Awai; Nobuaki Shime; Francesco Bonella; Josune Guzman; Hilmar Kühl; Ulrich Costabel; Noboru Hattori
Journal:  J Clin Med       Date:  2019-11-24       Impact factor: 4.241

4.  Impact and prognosis of lung cancer in patients with combined pulmonary fibrosis and emphysema.

Authors:  Jee Youn Oh; Young Seok Lee; Kyung Hoon Min; Gyu Young Hur; Sung Yong Lee; Kyung Ho Kang; Jae Jeong Shim
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-12-16       Impact factor: 0.670

5.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis with Lung Cancer: A Comparative Analysis of the Incidence, Survival Rate, and CT Findings with the Patients without Lung Cancer.

Authors:  Bumsang Cho; Hee Kang; Je Hun Kim; Jung Gu Park; Sekyoung Park; Jong Hyouk Yun
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2020-05-29

6.  Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis.

Authors:  Keishi Sugino; Hirotaka Ono; Natsumi Watanabe; Masahiro Ando; Eiyasu Tsuboi; Sakae Homma; Kazuma Kishi
Journal:  BMC Pulm Med       Date:  2021-07-10       Impact factor: 3.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.